H Allain

Summary

Country: France

Publications

  1. ncbi Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group
    H Allain
    Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculte de Medecine, Universite de Rennes I, Rennes
    Eur Neurol 44:22-30. 2000
  2. ncbi Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, Rennes, France
    Dement Geriatr Cogn Disord 10:181-5. 1999
  3. ncbi Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach
    D Bentue-Ferrer
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
    Clin Neuropharmacol 13:S9-25. 1990
  4. ncbi [Parkinson disease: interrogations and solutions]
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes
    Presse Med 26:909-15. 1997
  5. ncbi Clinical efficacy of almitrine-raubasine. An overview
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
    Eur Neurol 39:39-44. 1998
  6. ncbi [Psychiatry and clinical research. A dialogue with hospital directors]
    H Allain
    Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I
    Presse Med 29:1768-72. 2000
  7. ncbi Comparative effects of pharmacotherapy on the maintenance of cognitive function
    H Allain
    Department of Pharmacology, Faculte de Medecine, Universite de Rennes I, 2, avenue du professeur Leon Bernard, 35043 Rennes Cedex, France
    Eur Psychiatry 16:35s-41s. 2001
  8. ncbi [Perspectives for drug treatment in Alzheimer's disease]
    H Allain
    Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I, 2, avenue du Pr Leon Bernard, CS 34317, 35043 Rennes Cedex, France
    Ann Med Interne (Paris) 152:527-32. 2001

Collaborators

  • N Mauduit
  • D Bentue-Ferrer
  • C Schatz
  • J M Reymann
  • R Decombe

Detail Information

Publications8

  1. ncbi Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group
    H Allain
    Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculte de Medecine, Universite de Rennes I, Rennes
    Eur Neurol 44:22-30. 2000
    ..7 vs. 387.5 mg/day). Long-term follow-up demonstrated the L-dopa-sparing effect of lisuride (average 1 mg/day), the beneficial effect of early combination therapy on motor status and the paucity of motor complications in both groups...
  2. ncbi Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, Rennes, France
    Dement Geriatr Cogn Disord 10:181-5. 1999
    ....
  3. ncbi Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach
    D Bentue-Ferrer
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
    Clin Neuropharmacol 13:S9-25. 1990
    ....
  4. ncbi [Parkinson disease: interrogations and solutions]
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes
    Presse Med 26:909-15. 1997
    ..Since the inaugural description in 1817 by J. Parkinson, therapeutic progress rapidly accelerated mainly due to a better knowledge of the neurobiology of the central nervous system dopaminergic pathways...
  5. ncbi Clinical efficacy of almitrine-raubasine. An overview
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
    Eur Neurol 39:39-44. 1998
    ..The appropriate and usual dosage (2 tablets per day) and the good tolerance of the compound have been confirmed in a French multicentric study in 5,361 outpatients...
  6. ncbi [Psychiatry and clinical research. A dialogue with hospital directors]
    H Allain
    Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I
    Presse Med 29:1768-72. 2000
    ..Incentive politics as well as avoidance of technical and frequently definitive errors must be proned and issue from a deep analysis of how leading teams are organized and operate...
  7. ncbi Comparative effects of pharmacotherapy on the maintenance of cognitive function
    H Allain
    Department of Pharmacology, Faculte de Medecine, Universite de Rennes I, 2, avenue du professeur Leon Bernard, 35043 Rennes Cedex, France
    Eur Psychiatry 16:35s-41s. 2001
    ..As an illustration of this approach we shall relate two studies, TIATEM (phase I) and TIAGE (phase III/IV), leading to the determination of a good cognitive safety profile of an atypical neuroleptic drug, tiapride...
  8. ncbi [Perspectives for drug treatment in Alzheimer's disease]
    H Allain
    Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I, 2, avenue du Pr Leon Bernard, CS 34317, 35043 Rennes Cedex, France
    Ann Med Interne (Paris) 152:527-32. 2001
    ..The main goal of the present review is to summarize the state-of-the-art for a non specialist in AD...